Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10365143rdf:typepubmed:Citationlld:pubmed
pubmed-article:10365143lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10365143lifeskim:mentionsumls-concept:C0278678lld:lifeskim
pubmed-article:10365143lifeskim:mentionsumls-concept:C0076959lld:lifeskim
pubmed-article:10365143pubmed:issue2Clld:pubmed
pubmed-article:10365143pubmed:dateCreated1999-6-29lld:pubmed
pubmed-article:10365143pubmed:abstractTextTreosulfan is a bifunctional alkylating cytostatic agent that has mainly been used in the therapy of advanced ovarian cancer. Lately, a growth inhibiting effect could be detected in human renal cell carcinoma-cell lines as well. In vitro, Treosulfan showed an even higher growth inhibition than Vinblastine.lld:pubmed
pubmed-article:10365143pubmed:languageenglld:pubmed
pubmed-article:10365143pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10365143pubmed:citationSubsetIMlld:pubmed
pubmed-article:10365143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10365143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10365143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10365143pubmed:statusMEDLINElld:pubmed
pubmed-article:10365143pubmed:issn0250-7005lld:pubmed
pubmed-article:10365143pubmed:authorpubmed-author:BichlerK HKHlld:pubmed
pubmed-article:10365143pubmed:authorpubmed-author:WechselH WHWlld:pubmed
pubmed-article:10365143pubmed:authorpubmed-author:RigosDDlld:pubmed
pubmed-article:10365143pubmed:issnTypePrintlld:pubmed
pubmed-article:10365143pubmed:volume19lld:pubmed
pubmed-article:10365143pubmed:ownerNLMlld:pubmed
pubmed-article:10365143pubmed:authorsCompleteYlld:pubmed
pubmed-article:10365143pubmed:pagination1549-52lld:pubmed
pubmed-article:10365143pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:meshHeadingpubmed-meshheading:10365143...lld:pubmed
pubmed-article:10365143pubmed:articleTitleTreosulfan in the treatment of metastatic renal cell carcinoma.lld:pubmed
pubmed-article:10365143pubmed:affiliationDepartment of Urology, University of Tubingen, Federal Republic of Germany.lld:pubmed
pubmed-article:10365143pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10365143pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10365143pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed